DoD FY11 Prostate Cancer Exploration-Hypothesis Development Award

Post Date

April 21st 2011

Application Due Date

June 8th 2011

Funding Opportunity Number

W81XWH-11-PCRP-EHDA

CFDA Number(s)

12.420

Funding Instrument Type(s)

Cooperative Agreement
Grant

Funding Activity Categories

Science and Technology and other Research and Development

Number of Awards

30

Eligibility Categories

Unrestricted

Funding

• Estimated Total Funding:

  $3600000

• Award Range:

  $0 - $0

Grant Description

The PCRP Exploration ╔к_ Hypothesis Development Award mechanism was first offered in FY03. Since then, 1,056 Exploration ╔к_ Hypothesis Development Award applications have been received, and 142 have been recommended for funding. The Exploration ╔к_ Hypothesis Development Award supports the exploration of highly innovative, untested, potentially high-gain concepts, theories, paradigms, and/or methods that address an important problem in prostate cancer. Results of studies conducted through this award may provide the scientific rationale upon which a new hypothesis can be based, or initial proof-of-principle of an innovative hypothesis. This award is designed to provide investigators the opportunity to pursue serendipitous observations that may reveal entirely new avenues for investigation. Presentation of preliminary data is strongly discouraged. However, logical reasoning and a sound scientific rationale for the proposed work must be provided. All applications for the Exploration ╔к_ Hypothesis Development Award are highly recommended to address one of the FY11 PCRP overarching challenges. The PCRP seeks to fund projects from the wide spectrum of basic to clinical research; however, if the proposed project does not address one of the overarching challenges, the application should provide a description to justify how the project will nevertheless address a critical need in the field of prostate cancer research and/or patient care. Because these awards are designed for preliminary investigations, projects involving human subjects or specimens will not be supported unless they are exempt under 32 CFR 219.101(b) or eligible for expedited review (32 CFR 219.110 or 21 CFR 56.110). Additional information on the protection of human subjects and exempt or expedited review status may be found at https://www.bids.tswg.gov/. Also, for more information on clinical research, a Human Subject Resource Document is provided at https://cdmrp.org/Program_Announcements_and_Forms/. Applications proposing studies that do not qualify for exempt or expedited review status will be administratively withdrawn.

Contact Information

• Agency

  Department of Defense

• Office:

  Dept. of the Army -- USAMRAA

• Agency Contact:

  301-682-5507

• Agency Mailing Address:

  CDMRP Help Desk

• Agency Email Address:

  help@cdmrp.org